Anebulo Pharmaceuticals Investor Relations Material
Latest events
Q3 2025
13 May, 2025
Q2 2025
14 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Anebulo Pharmaceuticals Inc
Access all reports
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing treatments for acute cannabinoid intoxication (ACI) and substance abuse. Its primary product candidate, ANEB-001, is a cannabinoid receptor antagonist aimed at rapidly reversing the effects of cannabinoid overdose. The company is headquartered in Lakeway, Texas, and its shares are listed on the Nasdaq.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
ANEB
Country
🇺🇸 United States